Logo image of CDAK

CODIAK BIOSCIENCES INC (CDAK) Stock Fundamental Analysis

NASDAQ:CDAK - Nasdaq - US1920101060 - Common Stock - Currency: USD

0.057  -0.07 (-55.98%)

After market: 0.0399 -0.02 (-30%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CDAK. CDAK was compared to 551 industry peers in the Biotechnology industry. Both the profitability and financial health of CDAK have multiple concerns. CDAK has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CDAK has reported negative net income.
In the past year CDAK has reported a negative cash flow from operations.
CDAK Yearly Net Income VS EBIT VS OCF VS FCFCDAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

The profitability ratios for CDAK are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CDAK Yearly ROA, ROE, ROICCDAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CDAK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDAK Yearly Profit, Operating, Gross MarginsCDAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 -5K -10K -15K -20K

More info and screens

3

2. Health

2.1 Basic Checks

CDAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CDAK has less shares outstanding
CDAK has a better debt/assets ratio than last year.
CDAK Yearly Shares OutstandingCDAK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 20M 40M 60M 80M
CDAK Yearly Total Debt VS Total AssetsCDAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

CDAK has an Altman-Z score of -4.26. This is a bad value and indicates that CDAK is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CDAK (-4.26) is worse than 65.98% of its industry peers.
CDAK has a Debt/Equity ratio of 0.66. This is a neutral value indicating CDAK is somewhat dependend on debt financing.
CDAK's Debt to Equity ratio of 0.66 is on the low side compared to the rest of the industry. CDAK is outperformed by 78.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF N/A
Altman-Z -4.26
ROIC/WACCN/A
WACC7.64%
CDAK Yearly LT Debt VS Equity VS FCFCDAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 4.24 indicates that CDAK has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.24, CDAK is in line with its industry, outperforming 40.03% of the companies in the same industry.
CDAK has a Quick Ratio of 4.24. This indicates that CDAK is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.24, CDAK perfoms like the industry average, outperforming 40.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.24
Quick Ratio 4.24
CDAK Yearly Current Assets VS Current LiabilitesCDAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

CDAK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.88%, which is quite impressive.
Looking at the last year, CDAK shows a very strong growth in Revenue. The Revenue has grown by 101.86%.
EPS 1Y (TTM)44.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.18%
Revenue 1Y (TTM)101.86%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-54.88%

3.2 Future

The Earnings Per Share is expected to grow by 11.38% on average over the next years. This is quite good.
CDAK is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y41.06%
EPS Next 2Y26.88%
EPS Next 3Y19.35%
EPS Next 5Y11.38%
Revenue Next Year61.58%
Revenue Next 2Y-60.43%
Revenue Next 3Y-48.05%
Revenue Next 5Y-14.87%

3.3 Evolution

CDAK Yearly Revenue VS EstimatesCDAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
CDAK Yearly EPS VS EstimatesCDAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CDAK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDAK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDAK Price Earnings VS Forward Price EarningsCDAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDAK Per share dataCDAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as CDAK's earnings are expected to grow with 19.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.88%
EPS Next 3Y19.35%

More info and screens

0

5. Dividend

5.1 Amount

CDAK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CODIAK BIOSCIENCES INC

NASDAQ:CDAK (4/4/2023, 8:04:03 PM)

After market: 0.0399 -0.02 (-30%)

0.057

-0.07 (-55.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-15 2023-03-15
Earnings (Next)05-03 2023-05-03
Inst Owners0%
Inst Owner Change0%
Ins Owners1.56%
Ins Owner Change0%
Market Cap2.10M
Analysts82.86
Price Target9.18 (16005.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.15%
Min EPS beat(2)29.46%
Max EPS beat(2)64.85%
EPS beat(4)4
Avg EPS beat(4)44.47%
Min EPS beat(4)23.09%
Max EPS beat(4)64.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1128.75%
Min Revenue beat(2)-12.92%
Max Revenue beat(2)2270.42%
Revenue beat(4)3
Avg Revenue beat(4)713.06%
Min Revenue beat(4)-12.92%
Max Revenue beat(4)2270.42%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)55.17%
PT rev (3m)55.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.06
P/FCF N/A
P/OCF N/A
P/B 0.05
P/tB 0.05
EV/EBITDA N/A
EPS(TTM)-1.99
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.82
OCFYN/A
SpS0.93
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.08%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.24
Quick Ratio 4.24
Altman-Z -4.26
F-Score1
WACC7.64%
ROIC/WACCN/A
Cap/Depr(3y)307.3%
Cap/Depr(5y)323.95%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.18%
EPS Next Y41.06%
EPS Next 2Y26.88%
EPS Next 3Y19.35%
EPS Next 5Y11.38%
Revenue 1Y (TTM)101.86%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-54.88%
Revenue Next Year61.58%
Revenue Next 2Y-60.43%
Revenue Next 3Y-48.05%
Revenue Next 5Y-14.87%
EBIT growth 1Y30.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.06%
EBIT Next 3Y-0.38%
EBIT Next 5YN/A
FCF growth 1Y4.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.07%
OCF growth 3YN/A
OCF growth 5YN/A